MARKET SEGMENTS

(Size of Opportunity)

  • $1.2 Billion Viral infections in cancer patients
  • $4.8 Billion COPD
  • $2 Billion Severe Flu

MAJOR MARKETS EXIST FOR THIS TECHNOLOGY

Immunocompromised patients

Focus centered on high-risk patients undergoing chemotherapy.  Additional immunocompromised patients include ICU, elderly, HIV and other cancer patients.

Treating influenza

Current methods to treat the flu are inadequate. By locally stimulating the innate immune system in the respiratory system, the flu could be better prevented and treated. Additional government concerns deal with pandemic threats.

Patients with COPD

Nearly all exacerbations are a result of a viral infection. By preventing and treating the cause of the attack, the downstream complications can be minimized or eliminated.

PULMOTECT’S INITIAL MARKET FOCUS is on the reduction of pulmonary complications, including pnuemonia in immunocompromised cancer patients. Additional potential indications include prevention and treatment of respiratory viral infections , such as inluenza and reduction of chronic obstructive pulmonary disease (COPD) exacerbations. Exacerbations are characterized by an acute worsening of symptoms mostly precipitated by a bacterial or viral infection. COPD, which includes chronic bronchitis and emphysema, affects more than 24 million Americans and is the third leading cause of death in the U.S. There are five million COPD exacerbations a year in the U.S. with a 20% hospitalization rate.